Iannone F, et al. - The long-term efficacy and safety of tocilizumab, abatacept, and tumor necrosis factor-α inhibitors (TNFi) were assessed in the Italian real-world setting of rheumatoid arthritis (RA). It was concluded that the tocilizumab (TCZ) induced a rapid and long-lasting remission and in a higher percentage of patients compared to abatacept and TNFi in clinical practice with a good safety profile.